JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan International Research Enhanced Equity ETF
JIRE
|
+$4.16B |
| 2 |
Microsoft
MSFT
|
+$2.29B |
| 3 |
Amazon
AMZN
|
+$2B |
| 4 |
UnitedHealth
UNH
|
+$1.76B |
| 5 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.42B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$4.61B |
| 2 |
Vanguard Short-Term Bond ETF
BSV
|
+$1.58B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$689M |
| 4 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$659M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.28% |
| 2 | Technology | 15.04% |
| 3 | Healthcare | 12.52% |
| 4 | Financials | 10.55% |
| 5 | Consumer Discretionary | 7.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5076
Xeris Biopharma Holdings
XERS
$1.69B
| $123K | ﹤0.01% |
79,610
+60,955
| +327% | +$129K |
2018 Q3
15 quarters
|
|
5077
EyePoint Inc
EYPT
$278M
| $122K | ﹤0.01% |
15,447
-283
| -2% | -$2.85K |
2019 Q2
12 quarters
|
|
5078
Invesco S&P MidCap Quality ETF
XMHQ
$5.4B
| $122K | ﹤0.01% |
+1,921
| New | +$133K |
2022 Q2
0 quarters
|
|
5079
Evolv Technologies
EVLV
$853M
| $121K | ﹤0.01% |
45,311
+26,651
| +143% | +$70.9K |
2021 Q3
3 quarters
|
|
5080
Franklin Wireless
FKWL
$28.2M
| $121K | ﹤0.01% |
+37,360
| New | +$131K |
2022 Q2
0 quarters
|
|
5081
NatWest
NWG
$69B
| $121K | ﹤0.01% |
20,846
+11,125
| +114% | +$66.7K |
2014 Q2
32 quarters
|
|
|
TARO
5082
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $121K | ﹤0.01% |
3,340
+2,523
| +309% | +$96.2K |
2015 Q4
26 quarters
|
|
5083
Global X Copper Miners ETF NEW
COPX
$7.14B
| $120K | ﹤0.01% |
3,935
-4,627
| -54% | -$181K |
2019 Q3
11 quarters
|
|
|
FTHY
5084
First Trust High Yield Opportunities 2027 Term Fund
FTHY
$463M
| $120K | ﹤0.01% |
8,250
| – | – |
2021 Q4
2 quarters
|
|
5085
FVCBankcorp
FVCB
$317M
| $120K | ﹤0.01% |
8,003
-5,930
| -43% | -$94.9K |
2021 Q4
2 quarters
|
|
|
VORB
5086
DELISTED
Virgin Orbit Holdings, Inc. Common Stock
VORB
| $120K | ﹤0.01% |
+31,236
| New | +$155K |
2022 Q2
0 quarters
|
|
|
RKLY
5087
DELISTED
Rockley Photonics Holdings Limited
RKLY
| $120K | ﹤0.01% |
54,986
+33,587
| +157% | +$103K |
2021 Q4
2 quarters
|
|
5088
Alico
ALCO
$284M
| $119K | ﹤0.01% |
+3,352
| New | +$134K |
2022 Q2
0 quarters
|
|
|
CWBC
5089
Community West Bancshares
CWBC
$712M
| $119K | ﹤0.01% |
8,227
-6,762
| -45% | -$124K |
2016 Q2
24 quarters
|
|
5090
Hagerty
HGTY
$1.5B
| $119K | ﹤0.01% |
+10,395
| New | +$105K |
2022 Q2
0 quarters
|
|
5091
Hovnanian Enterprises
HOV
$685M
| $119K | ﹤0.01% |
2,792
+340
| +14% | +$16.5K |
2020 Q4
6 quarters
|
|
|
URG
5092
Ur-Energy
URG
$422M
| $119K | ﹤0.01% |
111,969
+25,016
| +29% | +$33.4K |
2021 Q2
4 quarters
|
|
5093
Amylyx Pharmaceuticals
AMLX
$3.58B
| $118K | ﹤0.01% |
6,132
+1,635
| +36% | +$19.4K |
2022 Q1
1 quarter
|
|
5094
Duluth Holdings
DLTH
$150M
| $117K | ﹤0.01% |
12,224
-10,407
| -46% | -$121K |
2017 Q3
19 quarters
|
|
5095
CALL
Intuit
INTU
$75.6B
| $116K | ﹤0.01% |
+300
| New | +$124K |
2022 Q2
0 quarters
|
|
5096
The Joint Corp
JYNT
$106M
| $116K | ﹤0.01% |
7,582
-8,630
| -53% | -$193K |
2019 Q1
13 quarters
|
|
|
CALY
5097
PUT
Callaway Golf Company
CALY
$2.56B
| $116K | ﹤0.01% |
+5,700
| New | +$123K |
2022 Q2
0 quarters
|
|
5098
UroGen Pharma
URGN
$1.98B
| $116K | ﹤0.01% |
14,059
-67,808
| -83% | -$466K |
2019 Q2
12 quarters
|
|
5099
United States Lime & Minerals
USLM
$3.19B
| $116K | ﹤0.01% |
5,475
-2,095
| -28% | -$47.4K |
2016 Q4
22 quarters
|
|
|
CAJ
5100
DELISTED
Canon, Inc.
CAJ
| $116K | ﹤0.01% |
5,119
+356
| +7% | +$8.59K |
2013 Q2
36 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2022 Portfolio in Review
As of Q2 2022, JP Morgan Chase held 7,270 positions worth $718B, down 14% from $830B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q2 2022 filing shows 568 new, 2,561 increased, 2,728 reduced and 609 closed positions. Its largest new stake was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B. The largest sale was JPMorgan BetaBuilders Europe ETF, an estimated $4.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q2 2022 buy was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B.
- JP Morgan Chase added most to Microsoft in Q2 2022, an estimated $2.29B increase.
- JP Morgan Chase's biggest Q2 2022 reduction was JPMorgan BetaBuilders Europe ETF, cutting an estimated $4.61B.
- JP Morgan Chase fully exited Cerner Corp in Q2 2022, selling an estimated $608M.
- JP Morgan Chase's ten largest holdings make up 18% of its $718B portfolio in Q2 2022.
- JP Morgan Chase opened 568 new positions and closed 609 in Q2 2022.
- JP Morgan Chase's portfolio value fell 14% quarter-over-quarter to $718B.
Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.